Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1973 1
1974 1
1975 1
1977 2
1979 2
1980 2
1981 1
1982 2
1983 2
1987 2
1988 1
1990 2
1991 2
1992 3
1993 6
1994 8
1995 5
1996 6
1997 5
1998 2
1999 6
2000 4
2001 13
2002 10
2003 14
2004 11
2005 16
2006 14
2007 16
2008 10
2009 29
2010 10
2011 21
2012 20
2013 30
2014 28
2015 29
2016 32
2017 26
2018 20
2019 19
2020 26
2021 23
2022 23
2023 22
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

490 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI. Plimack ER, et al. Among authors: waddell t. Eur Urol. 2023 Nov;84(5):449-454. doi: 10.1016/j.eururo.2023.06.006. Epub 2023 Jul 25. Eur Urol. 2023. PMID: 37500340
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI. Powles T, et al. Among authors: waddell t. Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23. Lancet Oncol. 2020. PMID: 33284113 Clinical Trial.
Static lung storage at 10°C maintains mitochondrial health and preserves donor organ function.
Ali A, Wang A, Ribeiro RVP, Beroncal EL, Baciu C, Galasso M, Gomes B, Mariscal A, Hough O, Brambate E, Abdelnour-Berchtold E, Michaelsen V, Zhang Y, Gazzalle A, Fan E, Brochard L, Yeung J, Waddell T, Liu M, Andreazza AC, Keshavjee S, Cypel M. Ali A, et al. Among authors: waddell t. Sci Transl Med. 2021 Sep 15;13(611):eabf7601. doi: 10.1126/scitranslmed.abf7601. Epub 2021 Sep 15. Sci Transl Med. 2021. PMID: 34524862
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, Guptal K, Maisey N, Khan M, Dent J, Lord S, Crossley A, Katona E, Marshall H, Grabsch HI, Velikova G, Ow PL, Handforth C, Howard H, Seymour MT; GO2 Trial Investigators. Hall PS, et al. Among authors: waddell t. JAMA Oncol. 2021 Jun 1;7(6):869-877. doi: 10.1001/jamaoncol.2021.0848. JAMA Oncol. 2021. PMID: 33983395 Free PMC article. Clinical Trial.
Engineering airway epithelium.
Soleas JP, Paz A, Marcus P, McGuigan A, Waddell TK. Soleas JP, et al. Among authors: waddell tk. J Biomed Biotechnol. 2012;2012:982971. doi: 10.1155/2012/982971. Epub 2012 Feb 8. J Biomed Biotechnol. 2012. PMID: 22523471 Free PMC article. Review.
CSPG4-targeting CAR-macrophages inhibit melanoma growth.
Greiner D, Xue Q, Waddell TQ, Kurudza E, Belote RL, Dotti G, Judson-Torres RL, Reeves MQ, Cheshier SH, Roh-Johnson M. Greiner D, et al. Among authors: waddell tq. bioRxiv [Preprint]. 2024 Jun 6:2024.06.04.597413. doi: 10.1101/2024.06.04.597413. bioRxiv. 2024. PMID: 38895447 Free PMC article. Preprint.
490 results